Novel PDACatch Assay Developed for Pancreatic Cancer Detection

Singlera Genomics developed PDACatch, a groundbreaking DNA methylation-based liquid biopsy assay specifically designed for the detection of pancreatic adenocarcinoma (PDAC) in individuals who are at high risk for developing the disease.

The PDACatch assay effectively identifies specific methylation patterns within circulating tumour DNA present in the blood. These methylation patterns are indicative of early-stage pancreatic adenocarcinomas, as well as precancerous lesions like intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN).

By examining specific methylation patterns associated with pancreatic cancer, the PDACatch assay aims to identify these alterations in the DNA of individuals at high risk of developing pancreatic ductal adenocarcinoma (PDAC).

The PDACatch assay leverages Singlera's MethylTitan platform, which utilises a proprietary library construction approach and methylation haplotypes to achieve high conversion rates and exceptional sensitivity in detecting cancer.

Pancreatic adenocarcinoma (PDAC) stands as a highly fatal cancer variant, primarily due to the prevalent occurrence of late-stage diagnoses. The five-year survival rate for PDAC is less than 10%, underscoring the severe prognosis associated with this disease.

The Breakthrough Device Designation granted to the PDACatch assay will expedite its availability as a screening option for individuals at high risk of pancreatic cancer.